iShares Biotechnology ETF | IBBRegistreer u om de ratings zichtbaar te maken |
Hoe heeft dit fonds gepresteerd? | 31-10-2024 |
Ontwikkeling van EUR 1000 (EUR) | Uitgebreide Grafiek |
Fonds | 15,6 | 8,6 | -8,0 | 0,2 | 5,3 | |
+/-Cat | -1,5 | -6,4 | 1,6 | 0,5 | -3,2 | |
+/-Idx | 9,0 | -18,9 | 5,0 | -17,8 | -12,7 | |
Categorie: Health | ||||||
Categorie Benchmark: MSCI ACWI NR USD |
Kerngegevens | ||
slotkoers 21-11-2024 | USD 136,10 | |
Rendement 1 Dag | 1,02% | |
Morningstar Categorie™ | Health | |
Vestigingsland | Verenigde Staten | |
Volume | 1305793 | |
Beurs | NASDAQ | |
ISIN | US4642875565 | |
Grootte Fonds (Mil) - | - | |
Grootte Fondsklasse (Mil) 21-11-2024 | USD 6771,00 | |
Lopende Kosten Factor - | -% |
Morningstar Research |
Beleggingsdoelstelling: iShares Biotechnology ETF | IBB |
The investment seeks to track the investment results of the NYSE Biotechnology Index composed of U.S.-listed equities in the biotechnology sector. The fund generally will invest at least 80% of its assets in the component securities of its underlying index and may invest up to 20% of its assets in certain futures, options and swap contracts, cash and cash equivalents. It is non-diversified. |
Returns | |||||||||||||
|
Management | ||
Naam manager Aanvangsdatum | ||
Greg Savage 01-01-2008 | ||
Jennifer Hsui 01-08-2012 | ||
Click here to see others | ||
Oprichtingsdatum 05-02-2001 |
Advertentie |
Categorie Benchmark | |
Benchmark van het fonds | Benchmark Morningstar |
NYSE Biotechnology TR USD | MSCI ACWI NR USD |
Target Market | ||||||||||||||||||||
|
Waar belegt het fonds in? iShares Biotechnology ETF | IBB | 19-11-2024 |
|
|
Top 5 posities | Sector | % |
Gilead Sciences Inc | Gezondheidszorg | 9,84 |
Vertex Pharmaceuticals Inc | Gezondheidszorg | 8,00 |
Amgen Inc | Gezondheidszorg | 7,43 |
Regeneron Pharmaceuticals Inc | Gezondheidszorg | 5,57 |
IQVIA Holdings Inc | Gezondheidszorg | 3,64 |
Toename Afname Nieuw t.o.v. vorige portefeuille | ||
iShares Biotechnology ETF | IBB |